Coeptis Therapeutics Welcomes Brian Cogley as New Chief Financial Officer

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is proud to announce the appointment of Brian Cogley, MBA, as the new Chief Financial Officer (CFO). With 15 years of experience in accounting and finance, Mr. Cogley has held positions of increasing authority at two of the world’s leading accounting firms, and has previously served on the management teams of various companies in a variety of industries. Christine Sheehy, who has been with Coeptis for years, will remain in a senior finance role and serve as the Vice President of Compliance and Corporate Secretary.

Mr. Cogley is joining Coeptis’ leadership team to lead the company’s financial and capital markets activities as it focuses on multiple anticipated growth drivers from its SNAP-CAR and GEAR™ programs and other opportunities.

Alongside Dave Mehalick, Chairman, President and Chief Executive Officer, and Dan Yerace, Director and Vice President of Operations, Mr. Cogley will help Coeptis reach its goals for future success.

We are thrilled to welcome Brian to the Coeptis Therapeutics team! His impressive background in advising public and private companies across numerous industries – particularly biotechnology and pharmaceuticals – evidences our commitment to bringing on board talented and experienced professionals.

Brian’s expertise in these areas will be invaluable to Coeptis as we move forward with the SNAP-CAR and GEAR programs and analyze new growth prospects. We look forward to having Brian join us and can’t wait to see what he can do!

Brian Cogley brings an impressive 15-year career in corporate finance and accounting to Coeptis. He has lent his expertise to a wide variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

Most recently, he served as a Senior Manager, Accounting Advisory at CFGI, LLC, where he was responsible for technical accounting implementations, interim Controller and SEC Reporting Manager roles, segment reporting, and carve-out engagements for pharmaceutical and financial services clients.

Mr. Cogley brings a wealth of experience to CFGI, having held various senior positions in finance and accounting. Most recently, he served as Vice President of Finance & Accounting at NexTier Bank, where he was part of the senior management team and led the bank’s accounting and finance operations.

Prior to NexTier, Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. Before that, he was a Financial Analyst at TriState Capital Bank, tasked with building Sarbanes-Oxley controls, SEC/regulatory reporting, and new system implementation.

Mr. Cogley is a highly experienced financial services expert, having begun his career at KPMG, LLP providing audit and assurance services to a variety of clients. His background is rooted in accounting and finance, having earned both a B.A. with a concentration in accounting and a Master of Business Administration with a concentration in finance from Duquesne University.

With his strong academic background and professional experience, Mr. Cogley is well-equipped to provide comprehensive financial services advice.

I am thrilled to join the team at Coeptis Therapeutics at such an exhilarating time for the Company. I am eager to use my financial expertise to support Dave and the rest of the management team to help Coeptis reach its growth potential and create value for both patients and shareholders with their diverse pipeline of cell and gene therapies and potential expansion opportunities.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., the parent company of Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is revolutionizing cancer treatments with its cutting-edge cell therapy platforms.

Building on a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, Coeptis is forging ahead with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

Instead of solely relying on in-license, out-license agreements, and co-development relationships, the company is also seeking strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Headquartered in Wexford, PA, Coeptis is on a mission to improve patient outcomes and disrupt conventional treatment paradigms.

Leave a Comment